Cell Freezing Media Market by Type, Application, End-Use

Description

List of Tables

[187 Pages Report] The Cell Freezing Media Market size was estimated at USD 185.71 million in 2023 and expected to reach USD 201.66 million in 2024, at a CAGR 8.71% to reach USD 333.25 million by 2030.

Cell freezing media is a specialized solution to preserve cells in extremely low temperatures. It comprises a balanced mixture of cryoprotectants, such as dimethyl sulfoxide (DMSO) and glycerol, protecting the cells from ice crystal formation during freezing. These cryoprotectants are crucial in minimizing cellular damage and maintaining cell viability and functionality upon thawing. The surging demand for advanced biopharmaceuticals and the growing cell therapy sector further contribute to the positive trajectory of the cell freezing media market. These therapies rely extensively on the preservation of cells, making the role of effective freezing media indispensable. However, the high cost of advanced preservation technologies and stringent regulatory requirements for cell handling and storage pose significant challenges for manufacturers and suppliers. Companies frequently work towards cutting costs and adhering to regulations to remain agile within the landscape. Expansion opportunities are seen in developing customized freezing solutions, growth in emerging markets, and integrating cutting-edge technologies such as AI and IoT to refine cryopreservation outcomes.

KEY MARKET STATISTICS
Base Year [2023]	USD 185.71 million
Estimated Year [2024]	USD 201.66 million
Forecast Year [2030]	USD 333.25 million
CAGR (%)	8.71%

Regional Insights

In America, the United States, and Canada stand at the forefront of the cell-freezing media market, owing to its robust biotechnology sector, substantial research and development investments, and major pharmaceutical companies. Innovations and patents in cryopreservation techniques and formulations are frequently reported, demonstrating a high demand for advanced cell freezing solutions. Adopting cell therapy and regenerative medicine further propels market growth in the region. The EMEA market for cell freezing media is advanced, strongly emphasizing quality, innovation, and compliance with stringent regulatory standards. The region's focus on stem cell research, personalized medicine, and biobanking contribute to a steady demand for sophisticated cell freezing solutions. Research collaborations and EU-funded initiatives play a significant role in market dynamics. The Middle East and Africa region are experiencing gradual growth in the cell freezing media market with rising investment in research activities, and increasing awareness about cell-based therapies contributes to market evolution. Moreover, the Asia Pacific region is experiencing a robust expansion in the cell freezing media market, owing to significant advancements in biotechnology and an increasing inclination towards cryopreservation methods for long-term cell storage. A rise in research and development activities, biobanking, and a surge in demand for regenerative medicine across countries such as China, Japan, and India further fuels this growth. Additionally, government initiatives aimed at bolstering healthcare infrastructure, along with growing investments in the pharmaceutical and biopharmaceutical sectors, are contributing to the positive trajectory of the market.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cell Freezing Media Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- The surging demand for advanced biopharmaceuticals and the consequent growth in biobanking activities
- Increasing investment in cell culture-based vaccines
- Growing preference for single-use technologies in biopharmaceutical production

Market Restraints
- High cost associated with cell biology research

Market Opportunities
- Advancements in regenerative medicine and the need for high-quality cryopreservation techniques
- Integration of advanced technologies such as AI and IoT in media cryopreservation

Market Challenges
- Strict regulatory requirements for the approval and use of cell freezing media

Market Segmentation Analysis
- Type: Utilization of Glycerol-based media in biopharmaceutical formulations to cater to sophisticated skin conditions
- End-Use: Increasing usage of cell freezing media in pharmaceuticals and biotechnology firms for novel drug discovery and development

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cell Freezing Media Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cell Freezing Media Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Sartorius completes acquisition of Polyplus

Sartorius, an entity in the life sciences sector, completed the acquisition of Polyplus through its subsidiary, Sartorius Stedim Biotech. Polyplus specializes in developing and producing pivotal transfection reagents in viral vector manufacturing. This acquisition augments Sartorius's capabilities in this domain and signifies Polyplus's expansion into complementary technologies. By venturing into plasmid design and protein and plasmid production, Polyplus is diversifying its offerings and enhancing its technological portfolio to better serve the evolving needs of gene-modified cell and gene therapies. [Published On: 2023-07-18]

Qkine and Sartorius Partnership Delivers a Complete Workflow Solution for the Analysis of Advanced Cell Models

Qkine partnered with Sartorius to enrich stem cell and organoid research by integrating Qkine's expertise in creating bioactive growth factors and cytokines with Sartorius's advanced portfolio of cell analysis technologies. Sartorius, celebrated for accelerating life science research and pharmaceutical development, offers a broad spectrum of products, including reagents, assays, and pioneering technologies such as automated cell culture and live-cell imaging. This partnership is positioned to propel advancements in biologic discovery, streamline cell line development processes, and enhance the development of sophisticated cell models, thus delivering a holistic workflow solution to the scientific community. [Published On: 2023-07-06]

ExCell Bio Launches a New Factory in Uruguay

ExCell Biotechnology Co., Ltd. celebrated the opening of its new facility, ARTICA BIOTECH S.A. This significant milestone occurred within the Zonamerica Free Trade Zone on the northeastern outskirts of Montevideo, Uruguay. ExCell Bio has distinguished itself through its dedication to innovation in developing upstream tools for the biopharmaceutical industry. The inauguration of ARTICA BIOTECH S.A. marks the company's second establishment in Uruguay. ExCell Bio has achieved a significant position in China's market segment with its serum product line, underscoring its commitment to excellence and growing influence in the global marketplace. [Published On: 2023-05-04]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cell Freezing Media Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cell Freezing Media Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, AMSBIO, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BPS Bioscience, Inc., Capricorn Scientific, Carl Roth GmbH + Co. KG, Celprogen Corporation, Charles River Laboratories, Elabscience Bionovation Inc., ExCell Biotechnology Co., Ltd, Funakoshi Co., Ltd., HiMedia Laboratories, Merck KGaA, NIPPON Genetics EUROPE GmbH, PAN-Biotech GmbH, PromoCell GmbH, Qiagen NV, Sartorius AG, STEMCELL Technologies, Thermo Fisher Scientific Inc., and WELGENE Inc..

Market Segmentation & Coverage

This research report categorizes the Cell Freezing Media Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Dimethyl Sulfoxide-based Media
- Glycerol-Based Media
- Serum-Free Media

Application
- Biobanking
- Cancer Research
- Genetic Engineering & CRISPR Technology
- Pharmaceutical Research & Development
- Regenerative Medicine
- Vaccine Development

End-Use
- Pharmaceutical & Biotechnology Companies
- Research Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-3F223D524794

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. The surging demand for advanced biopharmaceuticals and the consequent growth in biobanking activities
  - 5.1.1.2. Increasing investment in cell culture-based vaccines
  - 5.1.1.3. Growing preference for single-use technologies in biopharmaceutical production
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with cell biology research
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in regenerative medicine and the need for high-quality cryopreservation techniques
  - 5.1.3.2. Integration of advanced technologies such as AI and IoT in media cryopreservation
- 5.1.4. Challenges
  - 5.1.4.1. Strict regulatory requirements for the approval and use of cell freezing media
5.2. Market Segmentation Analysis
- 5.2.1. Type: Utilization of Glycerol-based media in biopharmaceutical formulations to cater to sophisticated skin conditions
- 5.2.2. End-Use: Increasing usage of cell freezing media in pharmaceuticals and biotechnology firms for novel drug discovery and development
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Cell Freezing Media Market, by Type

6.1. Introduction
6.2. Dimethyl Sulfoxide-based Media
6.3. Glycerol-Based Media
6.4. Serum-Free Media

7. Cell Freezing Media Market, by Application

7.1. Introduction
7.2. Biobanking
7.3. Cancer Research
7.4. Genetic Engineering & CRISPR Technology
7.5. Pharmaceutical Research & Development
7.6. Regenerative Medicine
7.7. Vaccine Development

8. Cell Freezing Media Market, by End-Use

8.1. Introduction
8.2. Pharmaceutical & Biotechnology Companies
8.3. Research Institutes

9. Americas Cell Freezing Media Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cell Freezing Media Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cell Freezing Media Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Sartorius completes acquisition of Polyplus
- 12.3.2. Qkine and Sartorius Partnership Delivers a Complete Workflow Solution for the Analysis of Advanced Cell Models
- 12.3.3. ExCell Bio Launches a New Factory in Uruguay
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio